MS
APTO

Maven Securities’s Aptose Biosciences, Inc. APTO Stock Holding History

Maven Securities’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-444
Closed -$1.18M – 919
2020
Q3 		$1.18M Buy
+444
New +$1.11M 0.1% 206
2020
Q1 		– Sell
-1,334
Closed -$3.45M – 468
2019
Q4 		$3.45M Buy
+1,334
New +$1.74M 0.31% 62

Other funds holding APTO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Maven Securities's APTO Position: Q4 2020 in Review

Maven Securities sold out of Aptose Biosciences, Inc. (APTO) in Q4 2020, closing a stake of 444 shares — an estimated $1.18M sold.

Maven Securities first reported a position in APTO in Q4 2019 and held it in 2 quarters. The position peaked at $3.45M in Q4 2019. 65 funds tracked by Wall St. Rank hold APTO as of Q4 2020.

  • Maven Securities reported no remaining Aptose Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Maven Securities sold 444 Aptose Biosciences, Inc. shares in Q4 2020, an estimated $1.18M.
  • Maven Securities first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 2 quarters.
  • Maven Securities's Aptose Biosciences, Inc. position peaked at $3.45M in Q4 2019.
  • 65 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.